Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE · Real-Time Price · USD
4.550
-0.150 (-3.19%)
Oct 30, 2025, 4:00 PM EDT - Market closed
Alterity Therapeutics Revenue
In the fiscal year ending June 30, 2025, Alterity Therapeutics had annual revenue of 5.44M AUD with 35.32% growth. Alterity Therapeutics had revenue of 3.83M in the half year ending June 30, 2025, with 150.44% growth.
Revenue (ttm)
5.44M AUD
Revenue Growth
+35.32%
P/S Ratio
22.19
Revenue / Employee
604,324 AUD
Employees
9
Market Cap
79.12M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 5.44M | 1.42M | 35.32% |
| Jun 30, 2024 | 4.02M | 102.95K | 2.63% |
| Jun 30, 2023 | 3.92M | -1.21M | -23.56% |
| Jun 30, 2022 | 5.12M | 783.93K | 18.06% |
| Jun 30, 2021 | 4.34M | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ATHE News
- 21 days ago - Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders - GlobeNewsWire
- 4 weeks ago - Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders - GlobeNewsWire
- 7 weeks ago - Alterity Therapeutics Raises A$20.0 million in Strategic Placement - GlobeNewsWire
- 2 months ago - Alterity Therapeutics to Present at the Biotech Showcase - GlobeNewsWire
- 3 months ago - Appendix 4C – Q4 FY25 Quarterly Cash Flow Report - GlobeNewsWire
- 3 months ago - Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy - GlobeNewsWire
- 3 months ago - Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study - GlobeNewsWire
- 4 months ago - Alterity Therapeutics to Provide Corporate Update in Fireside Chat - GlobeNewsWire